PA-EXONE
5.8.2020 14:02:13 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that the nickel-based alloy Inconel 718 has been certified as Third-Party Qualified, the company’s highest designation of material readiness for its metal 3D printers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005200/en/
Frequently used in the aerospace, energy and automotive industries, Inconel 718 is known for high strength and hardness, with strong resistance to corrosion, chemicals and extreme temperatures ranging from sub-zero to 1300° F. It also has outstanding welding characteristics, and is often used for high-temperature applications, such as jet engines and tooling, or corrosive environments, such as those featuring seawater or acids.
“Today’s qualification of Inconel 718, following on the heels of M2 Tool Steel earlier this year, shows the ExOne R&D team is aggressively delivering new materials for binder jet 3D printing,” said Rick Lucas, ExOne CTO and VP, New Markets. “Our increasing pace of material qualifications is a testament to the strength of our new metal 3D printer systems equipped with Triple ACT, an advanced compaction technology that is essential for binder jetting metals and other materials at high speeds and densities.”
As is the case with Inconel 718, ExOne’s patented Triple ACT enables 3D printing of standard MIM powders, followed by standard sintering profiles and heat treatments, that deliver high-density results consistent with wrought material. Independent testing verifies that Inconel 718 3D printed and sintered by ExOne meets ASTM standard B637-18 .
“ExOne can now transition R&D materials to full qualification as demand increases,” Lucas noted.
ExOne Material Qualification Levels
ExOne has three tiers of material qualification, to signify the varying levels of readiness of materials for binder jet 3D printing applications: R&D, Customer-Qualified and Third-Party Qualified.
Previously, ExOne had recognized Inconel 718 as an R&D material, which meant it had been deemed printable for researchers, supported by ongoing development. The new Third-Party Qualified status means that the material has passed rigorous ExOne tests over multiple builds and has verified material property data from an independent third party.
Customer-Qualified materials are those that have been qualified by ExOne customers with their own standards and are being successfully printed today for their own applications. However, they have not yet earned ExOne’s highest level of qualification for general market readiness.
ExOne has an aggressive roadmap to qualify new materials based on customer demand, and frequently works with major manufacturers to develop new materials to suit specific applications.
To date, 22 metal, ceramic and composite materials are now Third-Party or Customer-Qualified. The full list is available at www.exone.com/metalmaterials .
Additionally, more than two-dozen materials are recognized as R&D ready, including aluminum, which has been fast-tracked for qualification. ExOne believes the ability to 3D print aluminum at high speeds will have a transformative, sustainable effect on the automobile and aerospace industry.
CleanFuse Enables Binder Jetting of Premium Metals
ExOne’s proprietary CleanFuse binder was a critical component in the new qualification of Inconel 718. CleanFuse is a clean-burning binder for 3D printing metals that are sensitive to carbon left behind by other binding agents during sintering.
Binder jetting is a 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.
When binders don’t burn off cleanly during sintering, carbon residue can alter the chemistry and fundamental performance of some sensitive metals. Consequently, a benefit of 3D printing metals with CleanFuse is preserving consistent part performance, including a part’s ability to be welded. This is critical for aerospace, automotive or defense applications, where parts are often integrated or assembled into a final product.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005200/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
